Dr. Ben Park joined Anthem Blue Cross and Blue Shield in 1993 to start a large group of primary care physicians who would
institute a concept called managed care. Now American Health Network is
well-positioned to take advantage of the new version of managed care, called accountable care.
The U.S. Department of Justice has charged Ke-xue Huang, a native of China’s Hunan province, of stealing trade secrets of
a Dow AgroSciences insecticide and giving them to the People’s Republic of China. Federal agents arrested the former Dow Agro
scientist July 13 in Westboro, Mass.
Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
The Batesville-based maker of hospital beds and furniture announced Wednesday night that it earned $30.6 million in its third quarter, up from $20.2 million in the same quarter of 2009.
Indianapolis-based WellPoint Inc. became the third U.S. health insurer this month to increase its 2010 profit forecast, stirring
investor concern that state and federal regulators may increase scrutiny of industry pricing.
A U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
The Indianapolis-based health insurer raised its full-year profit forecast after it earned $722.4 million, 4 percent higher
than during the same quarter a year ago. Revenue and health plan membership fell.
When the Indiana Health Information Exchange launched in 2004, it was one of nine truly operational exchanges around the country.
Today, the Indianapolis-based organization is one of 73, according to the latest national survey by the eHealth Initiative.
Venture dollars for Indiana life sciences companies are still few, but the flow of deals is picking up. Nine Hoosier companies
scored investments totaling $10.4 million during the first six months of the year.
Marion County survey finds 80 percent of respondents in debt to local hospitals, with about half saying they were never informed
about the availability
of charity care or payment plans.
With the first baby boomers set to turn 65 in six months, investments in senior housing are heating up. A group of Indianapolis-area
professionals—including Mark Waterfill (left) and Tony Schantz—have banded together to launch three senior housing
projects around the state, spending $49 million and looking
to do more.
Investors are focused on whether Eli Lilly and Co. can continue dividend payments when patent expirations hit in the new few
years and whether the company's drug development pipeline can replace lost revenue.
Indianapolis-based drugmaker Eli Lilly and Co. recorded profits of $1.3 billion, or $1.22 per share, during the three months
ended June 30,
even after paying $27 million in severance to laid off employees.
Massachusetts-based Alnara Pharmaceuticals Inc. is a privately held company
developing an enzyme-replacement therapy for disorders of the pancreas.
Drugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
Indiana and other states face a struggle as they grapple with putting the health care changes into place in a relatively short
span of time while they also contend with the economic downtown and strained state budgets.
Clarian Health is launching its own health insurance plan, the boldest of several initiatives at Indianapolis hospitals to
bypass health insurers and provide health benefits directly to employers.
The Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
Nearly four months after President Barack Obama signed a health reform bill into law, businesses are still grappling with its
impact on the health benefits they offer their employees.
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
